Sarcoma

The addition of gemcitabine to pazopanib significantly increased the progression-free survival rate (PFSR) in patients with soft tissue sarcoma at 12 weeks compared to pazopanib alone, according to results of a phase 2 clinical trial.

Although the results suggested the combination seems to have clinical activity, the researchers advised phase 3 trials are needed to confirm.

In this multicenter, randomized phase 2…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. Nov 20, 2020

T-cell therapy shows durable response in soft tissue sarcoma

A durable response was found in patients with synovial sarcoma treated with ADP-A2M4 (Adaptimmune Therapeutics), according to data presented at the virtual Connective Tissue Oncology Society (CTOS) annual meeting.

Updated data from the phase 1 trial…

Journal Scan

  1. Jan 14, 2021

Gemcitabine/pazopanib combination shows clinical activity in soft-tissue sarcoma

The addition of gemcitabine to pazopanib significantly increased the progression-free survival rate (PFSR) in patients with soft tissue sarcoma at 12 weeks compared to pazopanib alone, according to results of a phase 2 clinical trial.